Filter By Category
Archives
Share on -
CRISANTASPASE
Generic Name: CRISANTASPASE
ABSTRACT -
Crisantaspase is an Erwinia-derived L-asparaginase enzyme used as part of multi-agent chemotherapy for acute lymphoblastic leukemia/lymphoblastic lymphoma when E. coli-derived asparaginase cannot be used because of hypersensitivity or silent inactivation.
DOSAGE -
- For Erwinia chrysanthemi asparaginase products, a common substitution regimen is 25,000 International Units/m2 intramuscularly or intravenously three times weekly (for example Monday, Wednesday, and Friday) for two weeks to replace each planned pegaspargase dose. Product-specific and recombinant crisantaspase schedules differ.
- always verify the exact marketed product, regimen, and oncology protocol.
SIDE EEFECTS -
Important adverse effects include hypersensitivity/anaphylaxis, pancreatitis, abnormal transaminases or hepatotoxicity, coagulation abnormalities including thrombosis and hemorrhage, hyperglycemia, nausea, vomiting, fever, abdominal pain, diarrhea, and injection/infusion-site reactions.
ALLERGIC REACTIONS -
Serious hypersensitivity including anaphylaxis can occur and may be life-threatening. Administer only where emergency treatment is available and monitor during and after administration. Erwinia-derived preparations may have limited cross-reactivity with E. coli-derived asparaginase, but allergic reactions still occur.
DRUG INTERACTIONS-
- Used with multi-agent chemotherapy. Timing and combination with vincristine, corticosteroids, methotrexate, anticoagulants, or hepatotoxic/myelosuppressive therapies can alter toxicity and efficacy.
- follow oncology protocol sequencing and monitoring.
PREAUTONS–
Specialist oncology use only. Monitor pancreatic enzymes, glucose, liver tests, bilirubin, triglycerides when indicated, coagulation parameters, bleeding/thrombosis, and asparaginase activity if protocol requires. Hold or discontinue for severe hypersensitivity, pancreatitis, thrombosis/bleeding, or severe hepatotoxicity according to protocol.
WARNINGS –
- Life-threatening anaphylaxis, pancreatitis, thrombosis/hemorrhage, hepatotoxicity, and hyperglycemia are major risks.
Share on -
. Developed by